Loading quotes...
Forecast
| Buy |
6 |
| Hold |
4 |
| Sell |
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -1.07m | 25.78% |
| EBITDA | 1.97m | 222.12% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €199.6m |
Number of shares | 14.79m |
52-week high/low | €14.16 - €10.28 |
| Dividends | No |
Beta | 1.42 |
P/E ratio | -183.35 |
PEG ratio | 0.06 |
P/B ratio | 11.55 |
P/S ratio | 0.00 |
Company profile
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
| Name | Merrimack Pharmaceuticals |
| CEO | Gary L. Crocker |
| Headquarters | Cambridge,
ma USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 29/03/2012 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | MACK |